Harmony Biosciences Announces Planned CEO Transition, Peter Anastasiou to Take Helm in 2027

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced a planned CEO transition as part of its Board of Directors' succession planning. Peter Anastasiou, current Sr. EVP and Chief Operating Officer, has been appointed President, Chief Executive Officer, and a member of the Board of Directors, effective January 1, 2027. Current CEO Jeffrey M. Dayno, M.D., will retire at the end of 2026. The company also reiterated its full-year 2026 WAKIX® net revenue guidance of $1.0 billion to $1.04 billion.